Dose response and efficacy of a live, attenuated human rotavirus vaccine in Mexican infants

OBJECTIVE

Immunization against rotavirus has been proposed as the most cost-effective intervention to reduce the disease burden associated with this infection worldwide. The objective of this study was to determine the dose response, immunogenicity, and efficacy of 2 doses of an oral, attenuated monovalent G1[P8] human rotavirus vaccine in children from the same setting in Mexico, where the natural protection against rotavirus infection was studied.

METHODS

From June 2001 through May 2003, 405 healthy infants were randomly assigned to 1 of 3 vaccine groups (virus concentrations 10(4.7), 10(5.2), and 10(5.8) infectious units) and to a placebo group and were monitored to the age of 2 years. The vaccine/placebo was administered concurrently with diphtheria-tetanus toxoid-pertussis/hepatitis B/Haemophilus influenzae type b vaccine at 2 and 4 months of age. After the administration of the first vaccine/placebo dose, weekly home visits to collect information regarding infant health were conducted. Stool samples were collected during each gastroenteritis episode and tested for rotavirus antigen and serotype.

RESULTS

The vaccine was well tolerated and induced a greater rate of seroconversion than observed in infants who received placebo. For the pooled vaccine groups, efficacy after 2 oral doses was 80% and 95% against any and severe rotavirus gastroenteritis, respectively. Efficacy was 100% against severe rotavirus gastroenteritis and 70% against severe gastroenteritis of any cause with the vaccine at the highest virus concentration (10(5.8) infectious units). The predominant infecting rotavirus serotype in this cohort was wild-type G1 (85%). Adverse events, including fever, irritability, loss of appetite, cough, diarrhea, and vomiting, were similar among vaccinees and placebo recipients.

CONCLUSION

This new oral, live, attenuated human rotavirus vaccine was safe, immunogenic, and highly efficacious in preventing any and, more importantly, severe rotavirus gastroenteritis in healthy infants. This vaccine produced comparable protection to natural infection.

Asymptomatic Shigella infections in a cohort of Mexican children younger than two years of age

The proportion of Shigella infections that occur asymptomatically in young children has not been established. A community-based cohort study of 367 infants was followed prospectively by weekly home visits from January, 1990, through December, 1991. Stool samples were collected weekly and when diarrhea occurred and were tested for Shigella and other enteropathogens. There were 2925 child months of observation and 65 episodes of Shigella infection. There were 3.1 episodes/100 child months during the warm season (May through September) and 0.97 episode/100 child months during the cold season. Shigella infections were rare during the first 6 months of life but increased with age (P < 0.0001). Overall 55% of detected infections were asymptomatic. The proportion of infections that were asymptomatic increased as age increased (P < 0.01). Symptom status was not significantly associated with Shigella species or season. All isolates from symptomatic and asymptomatic children had the 120- to 140-megadalton virulence plasmid. We conclude that infections with virulent strains of Shigella are commonly asymptomatic in Mexican children during the first 2 years of life.